Merck & Co., Inc. (MRK) Scheduled to Post Quarterly Earnings on Tuesday

Merck & Co., Inc. (NYSE:MRK) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, July 30th. Analysts expect the company to announce earnings of $2.14 per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.13. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.21 billion. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The company’s revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.40 EPS. On average, analysts expect Merck & Co., Inc. to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Merck & Co., Inc. Stock Down 0.5 %

MRK opened at $125.26 on Monday. Merck & Co., Inc. has a 12 month low of $99.14 and a 12 month high of $134.63. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.77. The business’s 50-day moving average price is $128.12 and its 200-day moving average price is $126.61. The company has a market cap of $317.26 billion, a P/E ratio of 139.18, a P/E/G ratio of 1.63 and a beta of 0.38.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, October 7th. Stockholders of record on Monday, September 16th will be issued a dividend of $0.77 per share. The ex-dividend date is Monday, September 16th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.46%. Merck & Co., Inc.’s dividend payout ratio is currently 342.22%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Morgan Stanley raised their target price on Merck & Co., Inc. from $132.00 to $134.00 and gave the company an “equal weight” rating in a research note on Thursday, July 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Merck & Co., Inc. in a research report on Tuesday, June 18th. Truist Financial upped their price target on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Berenberg Bank increased their target price on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Finally, Argus raised shares of Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $135.36.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.